Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan is a research paper published in JACC Heart Failure (2020). On theSindex it has a DataRank of 5.0. It has been cited 142 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.744
From this paper's citation signal
Citation Network Contribution
4.3
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
Pfizer
AbbVie
Abbott Laboratories
Janssen Pharmaceuticals
Medicines Company
Novo Nordisk
Roche
Servier
Takeda Pharmaceuticals U.S.A.
Boehringer Ingelheim
Bristol-Myers Squibb
MyoKardia
National Heart, Lung, and Blood Institute
Sanofi
Zora Biosciences
AstraZeneca
Bayer Fund
Boston Scientific Corporation
MedImmune
Zafgen
Daiichi-Sankyo
Eisai
GlaxoSmithKline
Amgen
Eli Lilly and Company
Janssen Research and Development
National Institutes of Health
Gilead Sciences
IFM Therapeutics
Merck
Novartis
Respicardia
FWCI
13.81
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals